Safety, feasibility

Lurbinectedin in the therapeutic landscape of SCLC: key clinical evidence and evolving role in the era of emerging therapies.

Despite recent therapeutic advances, durable disease control in small cell lung cancer (SCLC) remains challenging, particularly after relapse following platinum-based chemo-immunotherapy. Lurbinectedin, a selective inhibitor of oncogenic transcription, has emerged as a novel therapeutic agent with a distinct mechanism...

A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial.

A phase IIa trial evaluating avelumab, an anti-PD-L1 antibody, in relapsed/refractory PTCL demonstrated durable responses in a minority of patients, and most patients progressed early.

Immunotherapy with Pembrolizumab beyond Progression and Local Ablative Therapy in Oligoprogressive metastatic NSCLC.

In this retrospective analysis, treatment BPD was not associated with an improved prognosis compared to 2L therapy and there is a need to improve and implement criteria to select patients who truly benefit from this treatment approach.

Efficacy and safety profile of dMMR/MSI immunotherapy in metastatic colorectal cancer in real-world clinical practice

Introduction. Deficiency of the mismatch repair system (dMMR) and microsatellite instability (MSI) occur in only 4–5% of patients with metastatic colorectal cancer (mCRC), but this molecular subgroup is characterized by high sensitivity to immune checkpoint inhibitors. Data on the efficacy and safety of such thera...

Redefining second-line treatment strategy, sequencing, and real-world implementation in relapsed/refractory multiple myeloma: insights from the 31st Annual Congress of the European Hematology Association.

Integrating new and “old” cellular therapies in the evolving landscape of relapsed or refractory large B-cell lymphoma

Clinical management of R/R LBCL becomes highly complex in peculiar settings, especially in case of multiple relapses even after CAR T-cell therapy, as described in the clinical case of secondary central nervous system disease relapse.